Intranasal delivery of a polymeric nanoparticle subunit vaccine for the induction of protective immunity against respiratory syncytial virus - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Intranasal Administration of a Nanoparticle-Based Subunit Vaccine to Elicit Protective Immunity Against Respiratory Syncytial Virus

  • By

  • Sarah M. Ostrowski

  • Paul R. Hartmeier

  • Madeline A. Lipp

  • Timothy Perkins

  • Elliot Reed

  • Xiyue Li

  • Wilson S. Meng

  • Kerry M. Empey

  • June 26, 2026

Share

  • 1

    RSV is the leading cause of lower respiratory tract infections in children under 5, causing over 101,000 deaths annually worldwide.

  • 2

    Current maternal vaccines and monoclonal antibodies provide limited protection, highlighting the need for a direct childhood vaccine.

  • 3

    The intranasal subunit vaccine PreF-bNP demonstrated increased IL-12+ dendritic cells and established antiviral CD8 tissue resident memory T cells.

  • 4

    Immunization with PreF-bNP provided complete RSV protection for up to 8 weeks and reduced mucus production in the lungs of preimmune mice.

  • 5

    The study suggests that intranasal PreF-bNP is a promising candidate for further clinical development against RSV infection.

Original Source(s)

Intranasal delivery of a polymeric nanoparticle subunit vaccine for the induction of protective immunity against respiratory syncytial virus

  • by Sarah M. Ostrowski, Paul R. Hartmeier, Madeline A. Lipp, Timothy Perkins, Elliot Reed, Xiyue Li, Wilson S. Meng, Kerry M. Empey

  • June 26, 2026

Related Content

Why the Test-Negative Design Is Used for Routine Vaccine Monitoring

Effectiveness of varicella vaccine during a varicella outbreak in a Chinese senior high school: a retrospective cohort study

Interim Estimated Effectiveness of 2025-2026 COVID-19 Vaccines in Adults Using a Test-Negative Design